BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Pulusu SSR, Srinivasan A, Krishnaprasad K, Cheng D, Begun J, Keung C, Van Langenberg D, Thin L, Mogilevski T, De Cruz P, Radford-Smith G, Flanagan E, Bell S, Kashkooli S, Sparrow M, Ghaly S, Bampton P, Sawyer E, Connor S, Rizvi QUA, Andrews JM, Mahy G, Chivers P, Travis S, Lawrance IC. Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford. World J Gastroenterol 2020; 26(30): 4428-4441 [PMID: 32874055 DOI: 10.3748/wjg.v26.i30.4428]
URL: https://www.wjgnet.com/1007-9327/full/v26/i30/4428.htm
Number Citing Articles
1
Kengo Kanayama, Jun Kato, Wataru Shiratori, Ariki Nagashima, Yuki Ohta, Takashi Taida, Keiko Saito, Chihiro Goto, Satsuki Takahashi, Ryosuke Horio, Akane Kurosugi, Tsubasa Ishikawa, Tatsuya Kaneko, Naoki Akizue, Kenichiro Okimoto, Tomoaki Matsumura, Naoya Kato. Anti‐TNFα antibody versus non‐anti‐TNFα molecular agents for ulcerative colitis patients who failed initial anti‐TNFα therapy Journal of Gastroenterology and Hepatology 2022;  doi: 10.1111/jgh.15826
2
Daisuke Saito, Minoru Matsuura, Ryo Ozaki, Sotaro Tokunaga, Shintaro Minowa, Tatsuya Mitsui, Miki Miura, Akihito Sakuraba, Mari Hayashida, Jun Miyoshi, Tadakazu Hisamatsu. Clinical response of vedolizumab at week 6 predicted endoscopic remission at week 24 in ulcerative colitisJGH Open 2021; 5(9): 1056 doi: 10.1002/jgh3.12630
3
Bincy Abraham, Kerri Glassner. Positioning biologics and small molecules in the management of moderate to severe ulcerative colitisCurrent Opinion in Gastroenterology 2021; 37(4): 344 doi: 10.1097/MOG.0000000000000738
4
Javier P. Gisbert, María Chaparro. Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?Journal of Clinical Medicine 2021; 10(22): 5318 doi: 10.3390/jcm10225318
5
Mohamed Attauabi, Camilla Höglund, Janne Fassov, Kenneth Bo Pedersen, Heidi Bansholm Hansen, Signe Wildt, Michael Dam Jensen, Anders Neumann, Cecilie Lind, Henrik Albaek Jacobsen, Ana-Maria Popa, Jens Kjeldsen, Natalia Pedersen, Akbar Molazahi, Kent Haderslev, Claus Aalykke, Torben Knudsen, Wojciech Cebula, Pia Munkholm, Flemming Bendtsen, Jakob Benedict Seidelin, Johan Burisch. Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseasesScandinavian Journal of Gastroenterology 2021; 56(9): 1040 doi: 10.1080/00365521.2021.1946588
6
VedolizumabReactions Weekly 2020; 1833(1): 368 doi: 10.1007/s40278-020-87186-3
7
Carl Eriksson, Sara Rundquist, Vyron Lykiardopoulos, Ruzan Udumyan, Per Karlén, Olof Grip, Charlotte Söderman, Sven Almer, Erik Hertervig, Jan Marsal, Jenny Gunnarsson, Carolina Malmgren, Jenny Delin, Hans Strid, Mats Sjöberg, David Öberg, Daniel Bergemalm, Henrik Hjortswang, Jonas Halfvarson. Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH studyTherapeutic Advances in Gastroenterology 2021; 14: 175628482110233 doi: 10.1177/17562848211023386
8
Ann-Lorie Gagnon, William Beauchesne, Laurence Tessier, Charles David, Djamal Berbiche, Alexandre Lavoie, Alban Michaud-Herbst, Karine Tremblay. Adalimumab, Infliximab, and Vedolizumab in Treatment of Ulcerative Colitis: A Long-Term Retrospective Study in a Tertiary Referral CenterCrohn's & Colitis 360 2021; 3(4) doi: 10.1093/crocol/otab049
9
Mohamed Attauabi, Gorm Roager Madsen, Flemming Bendtsen, Jakob Benedict Seidelin, Johan Burisch. Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease – a systematic review with meta-analysisDigestive and Liver Disease 2021;  doi: 10.1016/j.dld.2021.11.014